Ginecología y Obstetricia de México

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Ginecología y Obstetricia de México >Year 2009, Issue 10

Quiroga DR, Cantú MR, Tello GHE, Puente VM, Montemayor GR, Martínez MA
Intrauterine misoprostol for the prevention of bleeding cesarean
Ginecol Obstet Mex 2009; 77 (10)

Language: Español
References: 13
Page: 469-474
PDF: 223.99 Kb.

Full text


Objective: To evaluate efficacy of misoprostol by intrauterine route for the prevention of the obstetrical hemorrhage and to know its effects collaterals.
Patients and methods: Clinical and randomized test with 200 patients to those who one took place to them Caesarean. The Group A was applied placebo and the group B misoprostol (group B; 800 µg) intrauterine, after the birth of its newborns. The necessity of additional uterotonics was compared, loss of hemoglobin and hematocrit, and the effects collaterals.
Results: In group B it diminished the necessity of additional uterotonics to 50% and the loss of hemoglobin in 39.6%. In the group greater loss of 3 was registered g of hemoglobin in 13 versus 3% of the patients. With respect to the hematocrit, its loss was reduced in 40.6%. The patients in those who the hematocrit in more fell than 10%, registered themselves in 7 versus 1% cases. The effects collaterals were few and not so serious.
Conclusion: The intrauterine combination of misoprostol and oxitocin diminishes the postcaesarean sanguineous loss and has brings about few effects collaterals.

Key words: Postcaesarean sanguineous loss, misoprostol, oxitocin.


  1. Printchard JA, Baldwin RM, Dicker JC, Wiggins KM. Blood volumen changes in pregnancy and the puerperium. Am J Obstet Gynecol 1962;84:1271-82.

  2. Clark SL, Yeh SY, Phelan JP, Bruce S, Paul RH. Emergency hysterectomy for obstetric hemorrhage. Obstet Gynecol 1984;64:376-80.

  3. Fernández CS. Índices de mortalidad materna. Dirección General de Estadística e Informática. Secretaría de Salud. México, 1990-1996.

  4. Turmen T. Safe motherhood: a global problem. Report from a symposium on the prevention and management of anaemia in pregnancy and postpartum hemorrhage. World Health Organization. Zurich, 1996:1-13.

  5. Drife J. Management of primary postpartum haemorrhage (commentary). Br J Obstet Gynaecol 1997;104:275-7.

  6. Hogerzeil HV, Walker GJA, de Goeje MJ. Stability of injectable oxytocics in tropical climates. Geneva: World Health Organization, 1993.

  7. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol 2006;108:1039-47

  8. Pendiville WL, Harding JE, Elbourne DR, Stirrat GM. The Bristol third stage trial:actives versus physiological management of third stage of labour. BMJ 1988;197:1295-300.

  9. el-Refaey H, Hinshaw K, Templeton A. The abortifacient effect of misoprostol in the second trimester. Hum Reprod1993;8:1744-6.

  10. Sánchez-Ramos L, Kaunitz AM. Misoprostol for cervical ripening and labor induction; a systematic review of the literature. Clin Obstet Gynecol 2000;43:475-88.

  11. el-Refaey H, O'Brien P, Morafa W, Walder J, Rodeck C. Use of oral misoprostol in the prevention of postpartum haemorrhage. Br J Obstet Gynaecol 1997;104;336-9.

  12. Bamigboye AA, Hofmeyr GJ, Merrell DA. Coronation HospitalJohannesburg, South Africa. Rectal misoprostol in the prevention of postpartum hemorrhage. Am J Obstet Gynaecol 1998:179;1043-6.

  13. Quiroga DR, Esparza AM. Misoprostol vaginal para la prevención de la hemorragia posparto. Ginecol Obstet Mex 2002;70:572-5.

>Journals >Ginecología y Obstetricia de México >Year 2009, Issue 10

· Journal Index 
· Links 

Copyright 2019